Results 201 to 210 of about 3,969,245 (300)

Tissue factor.

Blood & Vessel, 1987
Norio KOBAYASHI, Hiroshi TANAKA, Kiyoshi ANDOH, Toshimasa UCHIYAMA   +3 more
openaire   +2 more sources

Procoagulant Extracellular Vesicles Increase Neuronal Tau expression, Metabolism and Processing Through Tissue Factor and Protease Activated Receptor 2. [PDF]

Cell Mol Neurobiol
Featherby SJ, Faulkner EC, Gordon A, Ettelaie C.   +3 more
europepmc   +1 more source

Insights into a long life without cancer: The case of the bowhead whale

Molecular Oncology, EarlyView.
Long‐lived, large‐bodied organisms have evolved powerful anticancer mechanisms that preserve cellular and tissue integrity across extended lifespans. A recent study by Firsanov et al. shows that greater genome stability is a key factor underlying the remarkable longevity and cancer resistance of one such species, the bowhead whale.
Inés Paniagua, Johanna A. Joyce
wiley   +1 more source

Identification of the Interacting Domains Between Tissue Factor and β1-Integrin and the Signalling Properties of the Two Fibronectin-like Domains of Tissue Factor. [PDF]

Cancers (Basel)
Featherby SJ, Faulkner EC, Maraveyas A, Ettelaie C.   +3 more
europepmc   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Tissue factor [PDF]

Science-Business eXchange, 2013
openaire   +1 more source

Cryo-EM structure of the tissue factor/factor VIIa complex with a factor X mimetic reveals a novel allosteric mechanism. [PDF]

Blood
Sedzro JC, Photenhauer AL, Birkle F, Meze K, Mortenson A, Duckworth C, Wen PC, Kearns S, Cianfrocco MA, Tajkhorshid E, Ohi MD, Morrissey JH.   +11 more
europepmc   +1 more source

Molecular cancer prevention: Intercepting disease

Molecular Oncology, EarlyView.
Oncological practice must evolve, from treating established tumours to proactive cancer interception before clinical manifestation. This will require mechanistic insight into tumour initiation, validated biomarkers of early disease development and redesigned clinical trials, enabling cancer interception to become a core pillar of oncology with the ...
Charlotte Grieco, Tej Pandya, Charles Swanton   +2 more
wiley   +1 more source

Tissue factor expression in salivary gland carcinoma: a potential novel therapeutic target for advanced disease. [PDF]

Ther Adv Med Oncol
Jansen L, Nachtsheim L, Wolber P, Shabli S, Eßer J, Quaas A, Morris LGT, Ho AL, Klußmann JP, Arolt C, Mayer M.   +10 more
europepmc   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source